Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tim R Cressey

Showing results (91-100 of 166) with videos related to

Pageof 17
Sort By:
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|June 20, 2020
Plasma pharmacokinetics and urinary excretion of tenofovir following cessation in adults with controlled levels of adherence to tenofovir disoproxil fumarateTim R Cressey, Oraphan Siriprakaisil, Rachel W Kubiak, et al.
The Lancet. HIV|January 31, 2024
Paediatric abacavir-lamivudine fixed-dose dispersible tablets and ritonavir-boosted lopinavir granules in neonates exposed to HIV (PETITE study): an open-label, two-stage, single-arm, phase 1/2, pharmacokinetic and safety trialAdrie Bekker, Nicolas Salvadori, Helena Rabie, et al.
The Lancet. HIV|July 21, 2022
What babies need: accelerating access to current and novel antiretroviral drugs in neonates through pharmacokinetic studiesTom G Jacobs, Stef Schouwenburg, Martina Penazzato, et al.
Clinical Pharmacokinetics|May 27, 2020
Prediction of Maternal and Fetal Pharmacokinetics of Dolutegravir and Raltegravir Using Physiologically Based Pharmacokinetic ModelingXiaomei I Liu, Jeremiah D Momper, Natella Y Rakhmanina, et al.
Journal of Clinical Pharmacology|December 17, 2025
Population Pharmacokinetics of Bictegravir During Pregnancy and Postpartum: Role of Adherence in Maintaining Therapeutic ExposureSteven Sun, Mina Nikanjam, Mark Mirochnick, et al.
AIDS (London, England)|May 6, 2025
Assessment of the steady-state drug-drug interactions between dolutegravir and ritonavir-boosted darunavir in adolescentsSeef Abdalla, Alexandra Compagnucci, Alasdair Bamford, et al.
Journal of Clinical Pharmacology|January 11, 2016
A Population Pharmacokinetic/Pharmacodynamic Model Predicts Favorable HDL Cholesterol Changes Over the First 5 Years in Children Treated With Current Efavirenz-Based RegimensNontiya Homkham, Tim R Cressey, Lily Ingsrisawang, et al.
Plos Medicine|September 12, 2022
Continued attendance in a PrEP program despite low adherence and non-protective drug levels among adolescent girls and young women in Kenya: Results from a prospective cohort studyJean de Dieu Tapsoba, Jane Cover, Christopher Obong'o, et al.
Paediatric Drugs|October 22, 2024
Optimising Paediatric HIV Treatment: Recent Developments and Future DirectionsAnne E M Kamphuis, Alasdair Bamford, Alfredo Tagarro, et al.
The Journal of Antimicrobial Chemotherapy|February 5, 2019
Evaluating darunavir/ritonavir dosing regimens for HIV-positive pregnant women using semi-mechanistic pharmacokinetic modellingStein Schalkwijk, Rob Ter Heine, Angela Colbers, et al.
Pageof 17

Showing results (91-100 of 166) with videos related to

Sort By:
Pageof 17
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|June 20, 2020
Plasma pharmacokinetics and urinary excretion of tenofovir following cessation in adults with controlled levels of adherence to tenofovir disoproxil fumarateTim R Cressey, Oraphan Siriprakaisil, Rachel W Kubiak, et al.
The Lancet. HIV|January 31, 2024
Paediatric abacavir-lamivudine fixed-dose dispersible tablets and ritonavir-boosted lopinavir granules in neonates exposed to HIV (PETITE study): an open-label, two-stage, single-arm, phase 1/2, pharmacokinetic and safety trialAdrie Bekker, Nicolas Salvadori, Helena Rabie, et al.
The Lancet. HIV|July 21, 2022
What babies need: accelerating access to current and novel antiretroviral drugs in neonates through pharmacokinetic studiesTom G Jacobs, Stef Schouwenburg, Martina Penazzato, et al.
Clinical Pharmacokinetics|May 27, 2020
Prediction of Maternal and Fetal Pharmacokinetics of Dolutegravir and Raltegravir Using Physiologically Based Pharmacokinetic ModelingXiaomei I Liu, Jeremiah D Momper, Natella Y Rakhmanina, et al.
Journal of Clinical Pharmacology|December 17, 2025
Population Pharmacokinetics of Bictegravir During Pregnancy and Postpartum: Role of Adherence in Maintaining Therapeutic ExposureSteven Sun, Mina Nikanjam, Mark Mirochnick, et al.
AIDS (London, England)|May 6, 2025
Assessment of the steady-state drug-drug interactions between dolutegravir and ritonavir-boosted darunavir in adolescentsSeef Abdalla, Alexandra Compagnucci, Alasdair Bamford, et al.
Journal of Clinical Pharmacology|January 11, 2016
A Population Pharmacokinetic/Pharmacodynamic Model Predicts Favorable HDL Cholesterol Changes Over the First 5 Years in Children Treated With Current Efavirenz-Based RegimensNontiya Homkham, Tim R Cressey, Lily Ingsrisawang, et al.
Plos Medicine|September 12, 2022
Continued attendance in a PrEP program despite low adherence and non-protective drug levels among adolescent girls and young women in Kenya: Results from a prospective cohort studyJean de Dieu Tapsoba, Jane Cover, Christopher Obong'o, et al.
Paediatric Drugs|October 22, 2024
Optimising Paediatric HIV Treatment: Recent Developments and Future DirectionsAnne E M Kamphuis, Alasdair Bamford, Alfredo Tagarro, et al.
The Journal of Antimicrobial Chemotherapy|February 5, 2019
Evaluating darunavir/ritonavir dosing regimens for HIV-positive pregnant women using semi-mechanistic pharmacokinetic modellingStein Schalkwijk, Rob Ter Heine, Angela Colbers, et al.
Pageof 17